The MSO Problem: When Big Cannabis Takes Control.

A handful of large cannabis companies are fighting to shape who gets the licenses, the shelf space and the rules. The fallout reaches workers, consumers, neighbors and smaller operators trying to stay in business.

The Gatekeepers

Legal cannabis was supposed to be more than a way to buy weed without getting arrested. It was supposed to mean tested products, safer workplaces, access for patients and a real chance for local businesses. Legalization by itself does not make a market fair or safe.

Multistate operators, or MSOs, have money and reach across state lines. Some grow cannabis, process it and sell it in their own stores. That is vertical integration, and companies of every size do it. The structure is not the problem. The problem starts when a few companies control enough licenses, shelf space and political access to make it harder for everyone else to compete.

The records show different problems playing out in different places. In Texas, TCUP operators Texas Original and Goodblend hired lobbyists to support a THC ban that would have shut down sales of intoxicating hemp products and pushed legal THC sales into the state’s medical program, where both companies already operate. Massachusetts auditors found unlawful barriers in agreements between cannabis businesses and host communities. Regulators documented safety and environmental failures at specific facilities. In Ohio, the attorney general alleges that major operators made deals to keep independent brands off dispensary shelves. That case is pending. Each situation raises a basic question: who gets a shot at the legal market, and who has the power to shut others out?

When Licenses Are Scarce

Many states limit the number of cannabis licenses and require businesses to pay for security, tracking and reporting systems. Some medical programs also require vertical integration. A peer-reviewed study of state licensing found that medical markets tend to have fewer license categories and fewer licenses, along with higher costs and more vertical-integration requirements, than adult-use markets. A limited-license system may make oversight easier. It also leaves fewer ways in for new businesses.

Massachusetts shows what can happen. Cannabis businesses seeking a license had to reach agreements with host municipalities. The state auditor reviewed 26 agreements and found that 18 broke the law through excessive fees, mandatory donations or terms that lasted indefinitely. The auditor said weak oversight had created conditions in which only the largest businesses, often MSOs, could thrive. The audit did not blame every barrier on a national operator. It showed how local rules can favor applicants with deeper pockets and more legal support.

Getting a license is one fight. Getting on the shelf is another. Some companies own dispensaries; others depend on independent stores to carry their products. In a market with few outlets, shelf space can matter as much as a cultivation license. Ohio’s complaint alleges that major operators used reciprocal supply and shelf-space deals to limit independent brands. If proven, those arrangements would be competitors coordinating with one another, not simply companies choosing to run vertically integrated businesses.

The Ohio Allegations

In February 2026, Ohio’s attorney general filed an antitrust complaint against nine large operators: Ascend Wellness, Ayr Wellness, The Cannabist Company, Cresco Labs, Curaleaf, Green Thumb Industries, Jushi, Trulieve and Verano. The state alleges the companies used reciprocal supply arrangements, dispensary shelf-space commitments and exchanges of confidential promotional or pricing information to make it harder for independent Ohio businesses to compete. The complaint says those arrangements could limit consumer choice and keep prices higher. The allegations have not been tested in court.

The complaint calls some of the alleged arrangements “trade balances.” An operator would buy another company’s products or give them shelf space in one market, with the expectation of getting similar treatment elsewhere. The state cites emails about purchase targets, discounts and promotions. If the state proves its case, a brand’s access to stores depended partly on corporate deals, not just on what customers wanted to buy.

Ascend has denied the allegations and says it intends to fight them. The case will test whether the operators coordinated in ways that restricted competition. For independent brands, the concern is simple: a market is not much of an opportunity if the biggest players can decide who gets seen.

When Hemp Becomes the Competitor

Texas puts the fight over intoxicating hemp and market access in plain view. In 2025, lawmakers passed Senate Bill 3, which would have banned consumable hemp products containing THC. Gov. Greg Abbott vetoed it. The Houston Chronicle reported that Texas Original and Goodblend hired lobbyists to support the bill. Both are licensed dispensing organizations in the Texas Compassionate Use Program, or TCUP. Goodblend operates through Surterra Texas LLC, whose parent company, Surterra, is based in Florida.

The reporting links the companies to support for the bill, which would have removed a competing retail channel while keeping THC sales within Texas’s narrow medical program. That business consequence belongs in the discussion alongside the public-safety arguments. Consumers should not be forced into TCUP as their only legal option when Texas could set clear standards for established hemp retailers.

Some intoxicants sold outside licensed dispensaries are illicit marijuana or synthetic cannabinoids, even when marketed as hemp. That distinction gets lost when coverage repeats a seller’s label as if it proves what the product is. In a separate case, Army CID identified four smoke shops in Killeen and Copperas Cove as sources of illegal marijuana, THC products and synthetic cannabinoids sold to soldiers. Those findings concern specific shops, not licensed hemp businesses. Any safety argument should make that distinction and apply protections across retail channels.

Abbott’s veto did not end the fight. Texas rules that took effect March 31, 2026, require hemp sellers to count THCA toward total delta-9 THC after conversion. All high-THCA flower exceeds the state’s 0.3 percent limit under that calculation, effectively taking smokable flower off hemp retailers’ shelves. A court temporarily blocked parts of the rules, but an appeals court allowed them to take effect again in June while the legal challenge continues.

Texas hemp retailers say they put safeguards in place before the state required them. Wade Warner of Alamo Bud Co. told the San Antonio Express-News that his shop and other sellers checked IDs, limited sales to customers 21 and older, and used child-resistant packaging.

Texas was not the only state where regulated cannabis interests pushed for hemp restrictions. The U.S. Cannabis Council publicly supported a federal Farm Bill amendment to narrow the hemp definition and restrict intoxicating hemp products. In Missouri, the state cannabis trade association proposed moving many of those products into a cannabis-style regulatory framework and dispensary channel. Missouri and Illinois later enacted restrictions that substantially narrowed where such products could be sold.

Those laws have been defended as consumer protections. Their business effects deserve the same scrutiny. Smoke shops, convenience stores and small hemp brands can lose a category of business, while licensed cannabis companies may be positioned to capture some of that demand.

Federal rules are on a separate clock. A funding law passed in September delayed most of a new hemp definition, including a 0.4-milligram-per-container cap on THC and similar cannabinoids in finished products, from Nov. 12 to Dec. 11. Certain synthetic cannabinoids are still set to be excluded from hemp on Nov. 12. Unless Congress acts again, the broader restrictions take effect in December.

The cannabis industry has not spoken with one voice. Politico reported that Curaleaf, then a member of the U.S. Cannabis Council, disagreed with the council’s approach to hemp. Curaleaf was also selling a low-dose hemp-derived THC beverage. Major operators have not all backed the same restrictions. Still, licensed-cannabis trade groups have supported rules that could move hemp products into the dispensary channel their members already occupy.

There is a practical way to address consumer safety: set age limits, require accurate labels and testing, set manufacturing standards, and give regulators recall authority. Apply those protections wherever intoxicating cannabis products are sold. Instead, the rules shift with the product’s legal category and point of sale. That leaves gaps for consumers and gives the best-funded players an opening to shape which parts of the market survive.

Trulieve and the Politics of Access

Trulieve’s political spending has drawn scrutiny too. The company contributed nearly $145 million to the campaign for Florida’s 2024 Amendment 3, which would have legalized adult-use cannabis but did not authorize home cultivation. Curaleaf, Verano and Cresco also contributed. The measure won more than 55 percent of the vote, short of Florida’s 60 percent threshold.

Opponents called Amendment 3 a corporate “monopoly” measure. PolitiFact rated that specific claim false: the amendment did not itself create a monopoly, and the Legislature could authorize additional sellers. A legal scholar quoted in the fact-check said “oligopoly” better described the risk, because the measure did not require lawmakers to issue more licenses. The campaign did not prove Trulieve had captured the market. It did put a company with an enormous financial stake at the center of a fight over who would be allowed to sell.

People outside the industry saw the spending gap clearly. John Michael Pierobon, a Broward County tobacco-prevention advocate, told The Guardian that community groups could not match the campaign’s advertising. “I’m just a private citizen,” he said. The campaign did not settle the debate over adult-use legalization. It showed how hard it is for ordinary voters and community groups to compete with a company able to spend more than $100 million.

The Costs That Fall Outside the Store

Big companies can afford safety programs and environmental controls. The question is whether those programs protect people in practice.

Lorna McMurrey, a 27-year-old Trulieve employee, suffered an asthma attack while packaging ground cannabis into pre-rolls at the company’s Holyoke, Massachusetts, facility. She died in the hospital. Massachusetts regulators later found that Trulieve had not assessed cannabis dust as an allergen requiring respirators, had no safety-audit records after July 2021, and had not documented follow-up or reassessed the workplace after an earlier emergency involving McMurrey. The state had cited six deficiencies at the facility before her death.

In 2024, the Cannabis Control Commission approved a $350,000 settlement requiring new safety materials and procedures. Trulieve stipulated to the record facts without admitting or denying the commission’s findings. McMurrey’s family pursued a separate civil case.

Indoor cultivation also carries a significant energy cost. A 2025 life-cycle study estimated that U.S. cannabis production generates about 44 million metric tons of carbon-dioxide equivalent each year, with nearly 90 percent of emissions tied to indoor growing. That estimate covers the industry, not MSOs alone. It gives a sense of the environmental footprint as production expands.

At Trulieve’s Monticello cultivation site, water management became a neighborhood dispute before it became a state order. In April 2026, the Suwannee River Water Management District said inspections and information from an adjacent landowner showed apparent permit violations. The district cited unapproved paved areas, standing water, discharge continuing more than 30 days after rain, an expanding erosion scar and possible flows above the site’s predevelopment rate.

The district also reviewed samples collected by the neighbor during a pumping event. Its letter said tests showed “excessive pollutant leaving the site,” which “may be an additional violation.” Officials directed Trulieve to keep pumped water on its property or meet water-quality requirements without causing off-site harm. The letter described apparent violations and possible penalties. It did not find that nearby drinking water was contaminated.

In October, the Florida Department of Environmental Protection entered a separate consent order. DEP found that wastewater sprayed on an outdoor lawn had crossed the facility boundary without a permit. The order requires Trulieve to submit an irrigation plan and apply for a wastewater permit. The company must pay $80,000 or propose an environmental project worth at least $120,000 for DEP approval.

Trulieve did not admit that DEP’s findings constituted violations of law, but agreed to the order. The order does not find that neighboring drinking water or waterways were contaminated. Earlier testing reportedly found no contamination tied to the facility. Trulieve told WCTV it worked with DEP and remained committed to compliance. One neighbor welcomed the runoff action but said residents still wanted relief from “the odor and the sound.” The wastewater finding is one matter. Odor complaints, possible pollutants and resulting illness are separate issues, and the available record does not establish illness.

Massachusetts regulators also fined Curaleaf $80,000 in 2024 after finding failures in safeguards against pesticide contamination at two cultivation sites. Regulators cited multiple pesticide detections, including contaminated cannabis samples. Curaleaf said it destroyed affected product and added controls and training. Consumers should not have to rely on a company’s promises after a product fails. Safeguards have to work before it reaches the shelf.

The Mold Behind the Label

A passing test does not guarantee that flower will stay free of mold through its shelf life. States use different standards, and later stability tests can still find yeast or mold. The recalls described here do not establish that every affected package caused illness. They do raise basic questions about sampling, shelf life and whether customers find out about a problem in time.

In New Jersey, regulators investigated a patient complaint about cannabis grown by Curaleaf and dispensed by Green Thumb Industries. A state plant pathologist identified Penicillium in the patient’s sample. Additional samples showed fungal activity at both companies, and all three GTI samples developed visible fungal growth during testing. Regulators ordered product quarantined, required recalls and corrective plans, and directed both companies to add visual mold inspections to their quality procedures. They also found that the companies’ initial patient notices did not identify mold or Penicillium and offered little detail.

Connecticut regulators confirmed a voluntary Curaleaf recall in 2025 after a 60-day stability test found yeast and mold above acceptable levels in Curaleaf Whole Flower 3.5g Auburn. Curaleaf said the product passed initial testing and that the later result pointed to a shorter shelf life, not a widespread problem. In Arizona, Curaleaf recalled a Find Flower “Mac N Cheese” batch in 2023 after a failed Aspergillus test was confirmed on retest. The company said an error allowed the batch to leave production quarantine. Arizona’s recall notice reported no illnesses.

A 2024 Wall Street Journal analysis of more than two million state test results found mold readings clustering just below legal limits in several states. Brown biostatistician Joseph Hogan told the Journal that pattern “would not be expected” if labs reported results without regard to legal thresholds.

The Journal also found that Trulieve’s Holyoke plant sent 80 percent of its samples to one lab during a period when that lab’s mold-failure rate for Trulieve was one-sixth its rate at other labs handling the company’s samples. Trulieve said it chose state-approved labs based on capacity, turnaround and price; Massachusetts regulators had approved the lab’s methods. That difference in failure rates deserves scrutiny. It is not proof that Trulieve or the lab manipulated results.

Reuters found that states use different contaminant panels, sampling methods and thresholds. “Lab tested” can sound like a national guarantee. What it means depends on the state, the lab, the sample and the age of the product.

When the Biggest Operators Fail, Everyone Pays

These cases are not interchangeable. Regulators documented workplace safety failures before Lorna McMurrey died. Florida entered a consent order after finding wastewater crossed Trulieve’s property line without a permit. Mold recalls raise questions about testing and shelf life. Ohio’s antitrust allegations remain unproven. Each record has its own limits. Together, they show what is at stake when companies with enormous reach are not held to account.

The people who absorb the risk are rarely the people with the most power. Workers can be hurt on the job. Customers can be left unsure what a test means or how long a product is safe. Neighbors can be left dealing with runoff. Independent businesses can find that shelf space and political access are easier to get if they already have money and connections.

Legalization promised cannabis consumers something better than prohibition: products they can trust, workers protected by the law and businesses that can compete on their merits. Regulators should enforce labor, product-safety, environmental and competition rules no matter how large a company is. When lawmakers use safety to eliminate a competing retail channel, they should explain what risk the rule addresses, apply protections across the market and make clear who stands to benefit.

If the rules bend for the companies with the most money while workers, consumers, neighbors and small businesses carry the consequences, legalization will lose the trust it was supposed to earn. Bad MSOs do not just damage their own reputations. They give the entire legal cannabis industry a reason to answer for them.